Dear Huntington's Disease Community Partners,

Today, Skyhawk Therapeutics announced that the first participants in the United States have received study treatment in the global FALCON-HD clinical study evaluating SKY-0515, an investigational medicine being developed for Huntington's disease (HD).

We wanted to share this update directly with our patient advocacy partners and provide a brief summary of the announcement.

Key highlights:

- **First U.S. participants dosed:** Dosing has begun at the CenExel Movement Disorder Center in Colorado. Additional U.S. study sites, including Beth Israel Deaconess Medical Center in Massachusetts, are expected to begin dosing in the coming weeks.
- **Study progress:** The FALCON-HD clinical program is underway across more than 30 study sites in 10 countries.
- **FALCON-HD study:** The global study is evaluating the safety and effectiveness of SKY-0515, an investigational medicine taken once daily by mouth. Participants receive either SKY-0515 at one of three dose levels or a placebo (a treatment with no active medicine).
- **Ongoing recruitment:** The worldwide FALCON-HD study is actively recruiting participants with Huntington's disease, with plans to include more than 40 study sites globally.

SKY-0515 is designed to reduce levels of two proteins associated with Huntington's disease: mutant huntingtin (mHTT) and PMS1. It remains an investigational medicine, and its safety and effectiveness have not yet been established.

For additional information about FALCON-HD, including study locations and eligibility criteria, please visit **clinicaltrials.gov/study/NCT07378644**

We recognize the important contributions of individuals and families affected by Huntington's disease, as well as the investigators, study teams, and advocacy organizations supporting the HD community. We are grateful for your continued engagement and the perspectives you share, which help us better understand the needs and experiences of people living with HD.

We remain committed to keeping the HD community informed as the FALCON-HD program progresses and appreciate your ongoing partnership.

Sincerely,

The Skyhawk Therapeutics Team